New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
MannKind Corporation (MNKD) vs Novavax, Inc. (NVAX)
- MannKind Corporation MNKD 3.92 −0.51%
- Novavax, Inc. NVAX 7.74 +0.13%
MannKind Corporation and Novavax, Inc. are both Biotechnology companies. MannKind Corporation and Novavax, Inc. are of similar size ($1.4B and $1.3B). MannKind Corporation grew revenue faster over the last twelve months: 31.7% against −61.3%. MannKind Corporation has the higher net margin (−18.1% vs −18.6%) and the lower return on invested capital (−2.58% vs 0.00%). Across the 17 metrics below, MannKind Corporation leads on 11 and Novavax, Inc. on 6.
Valuation
Profitability
| Metric | MNKD | NVAX | Biotechnology median |
|---|---|---|---|
| Gross margin | 75.76% | 78.01% | 70.18% |
| Operating margin | (2.88%) | (21.23%) | 0.00% |
| Net margin | (18.10%) | (18.64%) | 0.00% |
| Free cash flow margin | (18.97%) | (59.09%) | 0.00% |
| Return on equity | 182.90% | 41.08% | (51.58%) |
| Return on assets | (12.29%) | (7.42%) | (45.91%) |
| Return on invested capital | (2.58%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack